This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tifacogin

Novartis AG

Drug Names(s): TFP561

Description: Tifacogin is a recombinant form of tissue factor pathway inhibitor (TFPI).

Deal Structure: Tifacogin was developed by Chiron in collaboration with Pharmacia & Upjohn, which was acquired by Pfizer. In October 2003, Chiron acquired all of Pfizers interest in tifacogin, in return for which Pfizer will receive royalties on sales of tifacogin. In April 2006, Novartis acquired Chiron.

Partners: Pfizer Inc.


Tifacogin News

Pink Sheet Tifacogin for CAP?


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug